Stranded on Antipsychotics: Role of the Pediatric Clinician

Correll CU. Antipsychotic medications. In: Dulcan MK , ed. Dulcan’s Textbook of Child and Adolescent Psychiatry. 2nd ed. Arlington, VA: American Psychiatric Association Publishing; 2016:795-846.

Sohn M Moga DC Blumenschein K Talbert J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore). 2016;95:e3784.

Loy JH Merry SN Hetrick SE Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2017;(8):CD008559.

Rettew DC Greenblatt J Kamon J , et al. Antipsychotic medication prescribing in children enrolled in Medicaid. Pediatrics. 2015;135:658-665.

Carton L Cottencin O Lapeyre-Mestre M , et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21:3280-3297.

Crystal S Mackie T Fenton MC , et al. Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain. Health Aff (Millwood). 2016;35:974-982.

Vanderwerker L Akincigil A Olfson M Gerhard T Neese-Todd S Crystal S. Foster care, externalizing disorders, and antipsychotic use among Medicaid-enrolled youths. Psychiatr Serv. 2014;65:1281-1284.

Glesener D Anderson G Li X , et al. Psychotropic medication patterns for American Indian children in foster care. J Child Adolesc Psychopharmacol. 2018;28:225-231.

Burcu M Zito JM Ibe A Safer DJ. Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications. J Child Adolesc Psychopharmacol. 2014;24:112-119.

Leckman-Westin E Finnerty M Scholle SH , et al. Differences in Medicaid antipsychotic medication measures among children with SSI, foster care, and income-based aid. J Manag Care Spec Pharm. 2018;24:238-246.

Zito JM Burcu M Ibe A Safer DJ Magder LS. Antipsychotic use by Medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade. Psychiatr Serv. 2013;64:223-229.

Brophy S Kennedy J Fernandez-Gutierrez F , et al. Characteristics of children prescribed antipsychotics: analysis of routinely collected data. J Child Adolesc Psychopharmacol. 2018;28:180-191.

Thackeray J Crane D Fontanella C Sorter M Baum R Applegate M. A Medicaid quality improvement collaborative on psychotropic medication prescribing for children. Psychiatr Serv. 2018;69:501-504.

De Hert M Detraux J van Winkel R Yu W Correll CU . Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114-126.

Galling B Roldán A Nielsen RE , et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73:247-259.

Ellul P Delorme R Cortese S. Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: a systematic review and meta-analysis. CNS Drugs. 2018;32:1103-1112.

Montejo AL Arango C Bernardo M , et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25-34.

Carbon M Kane JM Leucht S Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17:330-340.

Ray WA Stein CM Murray KT , et al. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry. 2019;76:162-171.

American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.

Wakefield S Aligeti M Rachamallu V , et al. Metabolic monitoring of child and adolescent patients on atypical antipsychotics by psychiatrists and primary care providers. Am J Ther. doi:10.1097/MJT.0000000000000853

Cerovecki A Musil R Klimke A , et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013;27:545-572.